Hematología y Hemoterapia

Resultados: 476
Tipo Título / Nombre Autor(es) Año
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry Aspas Requena G, Aguiar E, Brioso J, Ayala R..., Bergua Burgues JM 2026
Genomic and clinical landscape of RAS mutations in acute myeloid leukemia Rodríguez-Arbolí E, Soria-Saldise E, Barragan E, Ayala R..., Bergua Burgues JM 2026
Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy Paiva B, Burgos L, , , et al 2026
Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients Olszewski AJ, Eradat HA, Avigdor A, Horowitz NA..., Bergua Burgues JM 2026
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial Lonial S, Dimopoulos MA, Gavriatopoulou M, Kim K..., Casas-Avilés I 2026
Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia Bertoli S, Landberg N, Bérard E, Gondran C..., Bergua Burgues JM 2026
Early Use of Fostamatinib in Immune Thrombocytopenia González-López TJ, Bermejo Vega N, Cardesa-Cabrera R, Acedo N, Luis-Navarro J, Lakhwani S, et al 2026
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study Romero Riquelme MA, Aspas Requena G, Lloret-Madrid P, Gil C..., Bergua Burgués JM 2026
Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial Bernal T, Zambrano Márquez J, Rodríguez-Veiga R, Rodríguez-Arbolí E, Bergua-Burgués JM, Vives S, et al 2026
Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study Barragán E, Gil JV, Ayala R, Chillón C..., Bergua J 2026